Conestat alfa

Drug Profile

Conestat alfa

Alternative Names: Human C1 esterase inhibitor - Pharming; Recombinant human C1 esterase inhibitor - Pharming; rhC1INH; Rhucin; Ruconest

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharming Group NV
  • Class Complement C1 inactivator proteins; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Capillary leak syndrome; Delayed graft function
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase II Acute kidney injury
  • Preclinical Delayed graft function; Reperfusion injury
  • Discontinued Renal transplant rejection

Most Recent Events

  • 27 Nov 2017 Preregistration for Hereditary angioedema (In adolescents, Prevention, In adults) in USA (IV)
  • 04 Oct 2017 Conestat Alfa is still in phase II trials for Hereditary angioedema (In childrens, In adolescent) in Czech Republic, Germany, Italy, Israel, Poland, Macedonia, Slovakia and Romania
  • 29 Sep 2017 Safety and efficacy data from a phase II trial in Hereditary angioedema released by Pharming
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top